Liver and Bile

J Gastroenterol Hepatol. 2023;38(6):976–83

Mnatzaganian G, MacLachlan JH, Allard N, Brown C, Rowe S, Cowie BC

Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma


Background and aim: This study aimed to assess utilization of health-care services in people with decompensated cirrhosis (DC) or hepatocellular carcinoma (HCC) and a “late diagnosis” of hepatitis B or hepatitis C.
Methods: Hepatitis B and C cases during 1997–2016 in Victoria, Australia, were linked with hospitalizations, deaths, liver cancer diagnoses, and medical services. A late diagnosis was defined as hepatitis B or hepatitis C notification occurring after, at the same time, or within 2 years preceding an HCC/DC diagnosis. Services provided during the 10-year period before HCC/DC diagnosis were assessed, including general practitioner (GP) or specialist visits, emergency department presentations, hospital admissions, and blood tests.
Results: Of the 25,766 notified cases of hepatitis B, 751 (2.9%) were diagnosed with HCC/DC, and hepatitis B was diagnosed late in 385 (51.3%). Of 44,317 cases of hepatitis C, 2576 (5.8%) were diagnosed with HCC/DC, and hepatitis C was diagnosed late in 857 (33.3%). Although late diagnosis dropped over time, missed opportunities for timely diagnosis were observed. Most people diagnosed late had visited a GP (97.4% for hepatitis B, 98.9% for hepatitis C) or had a blood test (90.9% for hepatitis B, 88.6% for hepatitis C) during the 10 years before HCC/DC diagnosis. The median number of GP visits was 24 and 32, and blood tests 7 and 8, for hepatitis B and C, respectively.

Conclusions: Late diagnosis of viral hepatitis remains a concern, with the majority having frequent health-care service provision in the preceding period, indicating missed opportunities for diagnosis.

J.H. MacLachlan, WHO Collaborating Center for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, E-Mail: jennifer.maclachlan@mh.org.au

DOI: 10.1111/jgh.16162

Back to overview

this could be of interest:

A phase 3, randomized trial of bulevirtide in chronic hepatitis D

N Engl J Med. 2023;389(1):22–32

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomized, double-blind, placebo-controlled, phase 3 trial

Lancet. 2023;401(10391):1853–65

More articles on the topic